Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The denosumab and zoledronic acid groups were comparable at baseline, with no significant differences in age, sex distribution, BMI, serum calcium and phosphorus levels, BMD at any site, BTMs, eGFR, 25-hydroxyvitamin D, parathyroid hormone (PTH), prevalence of prior fractures, tobacco and alcohol use, or 10-year FRAX scores (P > 0.05 for all), indicating that the groups were well-matched (Table 1).
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes
Source: Article title.
This single-center, retrospective cohort study included patients diagnosed with osteoporosis at the First Affiliated Hospital of Guangxi University of Science and Technology between January 2021 and January 2023, patients were enrolled between January 2021 and January 2023.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes
Cohort study · Frontiers in Medicine · 2026
Original publication title
Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes
Copyright © 2026 Zou, Huang, Tang, Zhu, Li and Zhao.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To explore and compare the clinical efficacy and safety of denosumab versus zoledronic acid for the treatment of primary osteoporosis.
Source: ObjectiveAbstract: What methods does the paper describe?
This retrospective cohort study included 413 primary osteoporosis patients (denosumab, n = 198; zoledronic acid, n = 215). All received daily calcium (600 mg) and vitamin D (400 IU), representing the total combined daily intake from diet and supplements. The denosumab group received subcutaneous denosumab 60 mg every 6 months and the zoledronic acid group annual intravenous zoledronic acid 5 mg over 36 months. Outcomes assessed at baseline and after 36 months included bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip; bone turnover markers β-CTX (β-isomerized C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-terminal propeptide); pain severity using the Visual Analog Scale (VAS); functional impairment using the Oswestry Disability Index (ODI); and incidence of adverse reactions.
Source: MethodsAbstract: Results
After 36 months, BMD at all sites significantly increased from baseline in both groups (P < 0.001). The denosumab group demonstrated greater mean absolute increases in BMD at the lumbar spine (0.13 ± 0.10 vs. 0.10 ± 0.10 g/cm2, P < 0.001), femoral neck (0.14 ± 0.06 vs. 0.12 ± 0.05 g/cm2, P < 0.001), and total hip (0.09 ± 0.12 vs. 0.05 ± 0.09 g/cm2, P < 0.001) compared to the zoledronic acid group.
Both groups showed significant decreases in β-CTX and P1NP levels (P < 0.001), with the denosumab group exhibiting a greater reduction in β-CTX (−0.54 ± 0.47 vs. −0.34 ± 0.44 ng/mL, P < 0.001) and P1NP (−23.68 ± 5.44 vs. −19.98 ± 5.28 ng/mL, P < 0.001). VAS and ODI scores improved significantly in both groups (P < 0.001), with a greater reduction in the VAS score in the denosumab group (−5.17 ± 1.58 vs. −4.61 ± 1.48, P < 0.001).
The overall incidence of adverse reactions was lower in the denosumab group compared to the zoledronic acid group (5.56% vs. 20.00%, P = 0.008). Adverse events were collected via passive EMR retrieval (see Methods).
Source: ResultsAbstract: Conclusion
Over 36 months, both agents were effective. Denosumab was associated with greater BMD gains, stronger bone resorption suppression, and fewer recorded adverse reactions. These findings are hypothesis-generating and await prospective validation.
Source: ConclusionAuthors’ abstract
Objective
To explore and compare the clinical efficacy and safety of denosumab versus zoledronic acid for the treatment of primary osteoporosis.
Methods
This retrospective cohort study included 413 primary osteoporosis patients (denosumab, n = 198; zoledronic acid, n = 215). All received daily calcium (600 mg) and vitamin D (400 IU), representing the total combined daily intake from diet and supplements. The denosumab group received subcutaneous denosumab 60 mg every 6 months and the zoledronic acid group annual intravenous zoledronic acid 5 mg over 36 months. Outcomes assessed at baseline and after 36 months included bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip; bone turnover markers β-CTX (β-isomerized C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-terminal propeptide); pain severity using the Visual Analog Scale (VAS); functional impairment using the Oswestry Disability Index (ODI); and incidence of adverse reactions.
Results
After 36 months, BMD at all sites significantly increased from baseline in both groups (P < 0.001). The denosumab group demonstrated greater mean absolute increases in BMD at the lumbar spine (0.13 ± 0.10 vs. 0.10 ± 0.10 g/cm2, P < 0.001), femoral neck (0.14 ± 0.06 vs. 0.12 ± 0.05 g/cm2, P < 0.001), and total hip (0.09 ± 0.12 vs. 0.05 ± 0.09 g/cm2, P < 0.001) compared to the zoledronic acid group.
Both groups showed significant decreases in β-CTX and P1NP levels (P < 0.001), with the denosumab group exhibiting a greater reduction in β-CTX (−0.54 ± 0.47 vs. −0.34 ± 0.44 ng/mL, P < 0.001) and P1NP (−23.68 ± 5.44 vs. −19.98 ± 5.28 ng/mL, P < 0.001). VAS and ODI scores improved significantly in both groups (P < 0.001), with a greater reduction in the VAS score in the denosumab group (−5.17 ± 1.58 vs. −4.61 ± 1.48, P < 0.001).
The overall incidence of adverse reactions was lower in the denosumab group compared to the zoledronic acid group (5.56% vs. 20.00%, P = 0.008). Adverse events were collected via passive EMR retrieval (see Methods).
Conclusion
Over 36 months, both agents were effective. Denosumab was associated with greater BMD gains, stronger bone resorption suppression, and fewer recorded adverse reactions. These findings are hypothesis-generating and await prospective validation.
Publication and source details
Original title: Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes
Xin Zou; Xiaomeng Huang; Mingxin Tang; Yuyan Zhu; Cheng Li; Liangjun Zhao
Frontiers in Medicine · 2026
* Correspondence: Liangjun Zhao, zhaoliangjun163@163.comThese authors share first authorship
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:02:02.455621+00:00
DOI: 10.3389/fmed.2026.1842793 · PMC13461511